Mode
Text Size
Log in / Sign up
N/A N=68

Blood Flow, Muscle Regeneration and Sarcopenia

Sarcopenia

Enrolled (actual)
68
Serious AEs
2.9%
Results posted
Jan 2013
Primary outcome: Primary: Muscle Satellite Cells — 3.2; 3.2; 4.0; 3.8 Number of Pax7+ cells/muscle fiber

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Florida
Primary completion
Dec 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Muscle Satellite Cells
3.2; 3.2; 4.0; 3.8; 4.0; 3.7

Summary

Due to the rapid aging of the population, sarcopenia is among the greatest challenges facing the health care system over the next quarter century. This age-related loss of skeletal muscle mass and strength directly contributes to the incidence of functional disability, thereby reducing independence and quality of life for the elderly. Despite increasing efforts to combat sarcopenia, its etiology remains incompletely described. Subsequently, limited progress has been made in developing comprehensive preventative and therapeutic strategies to combat the problem. A decreased ability to regenerate skeletal muscle fibers through the donation of skeletal muscle stem cells (satellite cells) is thought to contribute to sarcopenia. However, the upstream physiological mediators that regulate this impairment are poorly delineated. Reduced muscle blood flow in advanced age appears to be a significant factor in reducing skeletal muscle regenerative capacity, but few data exist to confirm this hypothesis. Thus to test this hypothesis we aim to conduct a translational pilot trial which examines regeneration in both young and old adults. Furthermore, we aim to determine if muscle blood flow and satellite cell number are associated with muscle function. The central hypothesis of this proposal is that age-related declines in skeletal muscle angiogenesis and perfusion are significant causal factors in age-related losses of skeletal muscle mass. The specific aims and hypotheses of the project are as follows:

Eligibility Criteria

Inclusion Criteria

  • Men and women aged 18-30 years
  • Men and women aged > 70 years
  • Body mass index 120 min/week
  • Non-smoking

Exclusion Criteria

  • Active treatment for cancer, stroke ( 120 min/week).
  • Dementing illness
  • Smoking
  • Pregnant
  • Significant cognitive impairment; Mini-Mental State (MMSE) exam 2 drinks per day)
  • Resting heart rate > 120 bpm
  • Systolic blood pressure > 180 mmHg
  • Diastolic blood pressure > 110 mmHg
  • History of significant head injury
  • Anticholinesterase inhibitor (such as Aricept)
  • Contraindications to MRI (e.g. cardiac pacemaker, implanted cardiac defibrillator, aneurysm clip, claustrophobia, etc.)
  • Current Use of Antidepressant Medications
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01035060). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search